[Transduction of antisense RNA of MHC-II gene into CD3+ cord blood stem/progenitor cells inhibits the expression of HLA-DR antigen].
To explore whether the antisense RNA of HLA-DR gene could modulate the expression of the gene and reduce the immunogenicity of cord blood (CB) cells. A retroviral vector encoding antisense RNA of HLA-DR gene was constructed and transducted into packaging cell line PA317 by lipofectin. CD34+ hematopoietic stem cells/progenitors were sorted and enriched by MACS. A high titer (1 x 1095) cfu/ml) helper-free,virus producing cell PA317 was obtained. The vector was identified by blot hybridization and mapping of restriction points. The CD3+ CB cells were infected by the supernatant of the viral cultures. The G418-resistant clone was demonstrated to express the antisense RNA of HLA-DR gene by RT-PCR technique. The expression rate of HLA-DR antigen on CB cells was 28%, which was apparently lower than that of the control (45%) with an inhibition rate of 38.25%. The introduction of antisense RNA of HLA-DR gene into CB hematopoietic stem cells can successfully decrease the expression of HLA-DR antigen. These studies provide evidences for the prevention and treatment of GVHR in clinical CB transplantation.